The remaining 40% shareholding will be acquired in future as per certain terms and conditions, said Sun Pharmaceuticals Industries in its regulatory filing. It will be a cash transaction and is expected to be completed by May 2023. Vivaldis Health And Foods is engaged in the business of trading, distributing, manufacturing and marketing of drugs, food supplements and over the counter products in the companion animal segment of animal healthcare industry. Its revenue for the financial year 2021-22 was Rs 29.92 crore. The revenues have grown at CAGR of 47% during FY20 to FY22 period. Separately, the company issued an update regarding its recent Information Technology ("IT") security incident. On 2 March 2023, the drugmaker reported an IT incident at the company. A ransomware group has claimed responsibility for this incident.

The company said it promptly took steps to contain and remediate the impact of the IT breach, including employing containment and eradication protocols to mitigate the threat and additional measures to ensure the integrity of its systems infrastructure and data.

"As part of the containment measures, we proactively isolated our network and initiated the recovery process. As a result of these measures, Company's business operations have been impacted. Consequently, revenues are expected to be reduced in some of our businesses. The Company would incur expenses in connection with the incident and the remediation. The Company is currently unable to determine other potential adverse impacts of the incident, including but not limited to additional information security incidents, increased costs to maintain insurance coverage, the diversion of management and employee time or the possibility of litigation," the company said in a statement.

"As and when required, appropriate further notification(s) will be made on the IT security incident," the company said.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

The company reported 5.2% rise in consolidated net profit to Rs 2,166 crore in Q3 FY23 as compared with the corresponding quarter last fiscal. Total sales increased by 13% to Rs 11,100.14 crore in the third quarter from Rs 9,814.17 crore in the same period previous year.

The scrip rose 0.74% to end at Rs 980 on Friday, 24 March 2023.